Literature DB >> 29233750

Fibrin hydrogels as a xenofree and rapidly degradable support for transplantation of retinal pigment epithelium monolayers.

Jarel K Gandhi1, Zahid Manzar1, Lori A Bachman1, Cynthia Andrews-Pfannkoch1, Travis Knudsen1, Matthew Hill1, Hannah Schmidt1, Raymond Iezzi1, Jose S Pulido1, Alan D Marmorstein2.   

Abstract

Recent phase 1 trials of embryonic stem cell and induced pluripotent stem cell (iPSCs) derived RPE transplants for the treatment of macular degeneration have demonstrated the relative safety of this process. However, there is concern over clumping, thickening, folding, and wrinkling of the transplanted RPE. To deliver a flat RPE monolayer, current phase 1 trials are testing synthetic substrates for RPE transplantation. These substrates, however, cause localized inflammation and fibrosis in animal models due to long degradation times. Here we describe the use of thin fibrin hydrogels as a support material for the transplantation of RPE. Fibrin was formed into a mechanically rigid support that allow for easy manipulation with standard surgical instruments. Using fibrinolytic enzymes, fibrin hydrogels were degraded on the scale of hours. The rate of degradation could be controlled by varying the fibrinolytic enzyme concentration used. RPE cells degraded fibrin spontaneously. To preserve the fibrin support during differentiation of iPSCs to RPE, media was supplemented with the protease inhibitor aprotinin. iPSC-RPE on fibrin gels remained viable, generated monolayers with characteristic cobblestone appearance and dark pigmentation, and expressed mRNA and protein markers characteristic of RPE in the eye. Following differentiation of the cells, addition of fibrinolytic enzymes fully and rapidly degraded the fibrin support leaving behind an intact, viable iPSC-RPE monolayer. In conclusion, human fibrin hydrogels provide a xeno-free support on which iPSCs can be differentiated to RPE cells for transplant which can be rapidly degraded under controlled conditions using fibrinolytic enzymes without adverse effects to the cells. STATEMENT OF SIGNIFICANCE: Stem cell-derived retinal pigment epithelial (RPE) cell transplantation is currently in phase 1 clinical trials for macular degeneration (MD). A major obstacle in these studies is delivering the RPE as a living, flat sheets without leaving behind foreign materials in the retina. Here we investigate the suitability of using hydrogels made from human blood-derived proteins for RPE transplant. Our data shows that these fibrin hydrogels are rigid enough for use in surgery, support growth of stem cell-derived RPE, and are easily degraded within hours without damage to the RPE sheet. These fibrin hydrogels offer a promising solution to transplant RPE for patients with MD.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fibrin; Hydrogel degradation; Retinal pigment epithelium; Tissue engineering

Mesh:

Substances:

Year:  2017        PMID: 29233750     DOI: 10.1016/j.actbio.2017.11.058

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  8 in total

Review 1.  Hydrogel-based ocular drug delivery systems: Emerging fabrication strategies, applications, and bench-to-bedside manufacturing considerations.

Authors:  Remy C Cooper; Hu Yang
Journal:  J Control Release       Date:  2019-05-22       Impact factor: 9.776

2.  Methodological Approach to Improve Surgical Outcomes of a Pig Subretinal Implantation Model.

Authors:  Fukutaro Mano; Jarel K Gandhi; Raphael Pereira da Silva; Aline Do Amaral Silva; Lucas Iezzi; Raymond Iezzi; Jose S Pulido; Alan D Marmorstein
Journal:  Transl Vis Sci Technol       Date:  2022-04-01       Impact factor: 3.048

3.  Human Fibrinogen for Maintenance and Differentiation of Induced Pluripotent Stem Cells in Two Dimensions and Three Dimensions.

Authors:  Jarel K Gandhi; Travis Knudsen; Matthew Hill; Bhaskar Roy; Lori Bachman; Cynthia Pfannkoch-Andrews; Karina N Schmidt; Muriel M Metko; Michael J Ackerman; Zachary Resch; Jose S Pulido; Alan D Marmorstein
Journal:  Stem Cells Transl Med       Date:  2019-02-15       Impact factor: 6.940

4.  Fibrin hydrogels are safe, degradable scaffolds for sub-retinal implantation.

Authors:  Jarel K Gandhi; Fukutaro Mano; Raymond Iezzi; Stephen A LoBue; Brad H Holman; Michael P Fautsch; Timothy W Olsen; Jose S Pulido; Alan D Marmorstein
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

5.  The degradation of gelatin/alginate/fibrin hydrogels is cell type dependent and can be modulated by targeting fibrinolysis.

Authors:  Elea Boucard; Luciano Vidal; Flora Coulon; Carlos Mota; Jean-Yves Hascoët; Franck Halary
Journal:  Front Bioeng Biotechnol       Date:  2022-07-22

Review 6.  A Comprehensive Review of Cross-Linked Gels as Vehicles for Drug Delivery to Treat Central Nervous System Disorders.

Authors:  Leshasha T Mashabela; Mahlako M Maboa; Ntombi F Miya; Taiwo O Ajayi; Rumbidzai S Chasara; Marnus Milne; Shoeshoe Mokhele; Patrick H Demana; Bwalya A Witika; Xavier Siwe-Noundou; Madan S Poka
Journal:  Gels       Date:  2022-09-06

7.  Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.

Authors:  Jina Youn; Joo Hee Choi; Sumi Lee; Wonchan Lee; Seong Won Lee; Wooyoup Kim; Youngeun Song; Nomin-Erdene Tumursukh; Jeong Eun Song; Gilson Khang
Journal:  Molecules       Date:  2022-08-27       Impact factor: 4.927

8.  Subretinal Implantation of Human Primary RPE Cells Cultured on Nanofibrous Membranes in Minipigs.

Authors:  Lyubomyr Lytvynchuk; Annabelle Ebbert; Hana Studenovska; Richárd Nagymihály; Natasha Josifovska; David Rais; Štěpán Popelka; Lucie Tichotová; Yaroslav Nemesh; Jana Čížková; Jana Juhásová; Štefan Juhás; Pavla Jendelová; Janka Franeková; Igor Kozak; Slaven Erceg; Zbynek Straňák; Brigitte Müller; Zdenka Ellederová; Jan Motlík; Knut Stieger; Taras Ardan; Goran Petrovski
Journal:  Biomedicines       Date:  2022-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.